NeuroSense Therapeutics is set to participate in the 5th Annual ROTH Healthcare Opportunities Conference, discussing key advancements in neurodegenerative disease treatments.

NeuroSense Therapeutics (NRSN) Chief Financial Officer Or Eisenberg will attend the 5th Annual ROTH Healthcare Opportunities Conference on September 29, 2026.He will meet with institutional investors in New York City. Expected topics include clinical and regulatory progress with PrimeC, its ALS drug candidate, and the company’s strategy toward potential regulatory approval in Canada, the U.S. and other markets.

NeuroSense Therapeutics provides a comprehensive update on its strategic initiatives and financial outcomes for the first half of 2026, highlighting progress with its ALS therapy, PrimeC.

Neurosense Therapeutics is revamping its development plan for PrimeC, an experimental oral treatment for amyotrophic lateral sclerosis (ALS).

Reported Monday, Aug 31 - 8:53am EDT (TheFly subscription required to read more.)

NeuroSense Therapeutics announces a revised strategy to accelerate PrimeC's path to potential ALS approval while controlling costs. This innovative approach includes AI analysis and comparative trials.

Three-part program - AI-enabled characterization of PrimeC's formulation advantage, an active-comparator trial against edaravone, and a streamlined pivotal pathway - is designed to strengthen PrimeC's differentiation, shorten the time to potential commercialization, and significantly...

Stock Titan provides an ultra-fast stock market news feed and multiple tools for traders and investors.

NeuroSense Therapeutics shares critical updates on their Phase 3 PARAGON study for ALS, regulatory opportunities, and financial strategy to shareholders.

NeuroSense Therapeutics is set to submit a New Drug Application to Health Canada for PrimeC, aimed at improving treatment options for ALS by December 2026.

Final meeting minutes reflect alignment with Health Canada on the planned content and structure of the ALS submission CAMBRIDGE, Mass., Aug. 6, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on...

Reported Thursday, Aug 6 - 11:30am EDT (TheFly subscription required to read more.)

Health Canada has also indicated that it has no concerns with the Company's proposed filing timeline and advised the Company to target early December. NDS is the Canadian equivalent of a New Drug Application in the United States. "Our team is advancing the remaining clinical, biomarker, manufacturing and regulatory components of the NDS, with the objective of...

NeuroSense Therapeutics is moving PrimeC one step closer to a Canadian regulatory filing, keeping its ALS story focused on a possible accelerated path to market

NeuroSense is set to file a New Drug Submission for PrimeC to treat ALS, following crucial data from their Phase 2b study, enhancing their prospects.

Reported Wednesday, Jul 22 - 8:34am EDT (TheFly subscription required to read more.)

The planned submission follows alignment with Health Canada on the NDS pathway and is supported by additional PARADIGM data, including a survival benefit and consistent effects across PrimeC's multi-pathway biomarker program CAMBRIDGE, Mass., July 22, 2026 /PRNewswire/ -- NeuroSense...

NeuroSense Therapeutics (NASDAQ: NRSN) plans to file a New Drug Submission (NDS) with Health Canada for its ALS drug candidate PrimeC, following a constructive Pre-NDS meeting and alignment on the regulatory pathway. The company expects to complete and submit the NDS in the coming months.According to NeuroSense, the planned submission will be supported by new Phase 2b PARADIGM data, including achievement of the prespecified primary TDP-43 biomarker endpoint (p=0.0421) and a 14.9‑month median survival benefit (HR 0.35; p=0.0037), along with external natural history analyses and additional mechanistic and translational evidence.

NeuroSense Therapeutics will join a KOL webinar led by Roth to discuss unmet needs in ALS treatment and future directions for potential therapies.

NeuroSense now has FDA clearance to take PrimeC to Phase III in ALS, as competition in the indication intensifies.